This technology is a patient-derived 3D organoid model of colorectal cancer suitable for drug screening and personalized therapeutic development.
Colorectal cancer is the second leading cause of cancer death worldwide. Current models for screening potential therapeutics for colorectal cancer include 2D cell lines and patient-derived xenografts. However, therapeutics tested with these models often appear effective but then fail to show efficacy in the clinic. New models and screening platforms that more accurately represent the patient-specific tumor diversity and the tumor microenvironment are needed.
This technology is a patient-derived 3D organoid model for colorectal cancer. This model preserves colorectal tumor architecture and function by embedding patient-derived colorectal tumor cells in an extracellular matrix scaffold. By maintaining the tumor structure and genetics from the patients, this model allows for more accurate prediction of therapeutic efficacy. Additionally, the patient-derived nature of these organoids enables the development of personalized therapeutics and the identification of novel biomarkers.
This technology has been validated with human colorectal tumor samples.
IR CU26010
Licensing Contact: Joan Martinez
